New CDC interim guidance recommends a 4-month Rifapentine-Moxifloxacin regimen to treat drug-susceptible pulmonary tuberculosis.

Interim Guidance: 4-Month Rifapentine-Moxifloxacin Regimen for the Treatment of Drug-Susceptible Pulmonary Tuberculosis — United States, 2022 – CDC Morbidity and Mortality Weekly Report

Related:

Summary | WHO recommendations on the treatment of drug-resistant tuberculosis, 2020 update.

WHO Guideline: Screening for Tuberculosis Disease

New WHO Recommendations to Prevent Tuberculosis

CDC Guidelines for the Treatment of Latent Tuberculosis Infection

Guideline: Treatment of Drug-Resistant Tuberculosis

NICE Guideline: Tuberculosis

The Lancet Commission: Management of Multidrug-resistant and Incurable Tuberculosis

Regimens to Treat Multidrug-resistant Tuberculosis: Past, Present and Future Perspectives

Guidelines for the Management of TB in Adults Living with HIV

Commentary on Twitter

Clinicians: @CDC_TB released interim guidance on a new regimen to treat #TB disease. Learn more about the 4-month regimen containing rifapentine, moxifloxacin, isoniazid, and pyrazinamide for people with drug-susceptible pulmonary TB disease in the U.S.: https://t.co/eOcR34tYJu pic.twitter.com/EFGMwAwN7c

— MMWR (@CDCMMWR) February 25, 2022